Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators

European Urology

Volumn 71, Issue 2, 2017, Pages 183-192

  Wei, Lei ^a   Wang, Jianmin ^a   Lampert, Erika ^b   Schlanger, Simon ^b   DePriest, Adam D ^a   Hu, Qiang ^a   Gomez, Eduardo Cortes ^a   Murakam, Mitsuko ^a   Glenn, Sean T ^a   Conroy, Jeffrey ^a   Morrison, Carl ^a   Azabdaftari, Gissou ^a   Mohler, James L ^a   Liu, Song ^a   Heemers, Hannelore V ^b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Actionable target; Active surveillance; Androgen deprivation therapy; Castration; Indolent; Personalized medicine; Prostatic adenocarcinoma; Radiation therapy; Somatic alterations

Indexed keywords

ANDROGEN RECEPTOR; FLI1 PROTEIN; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; ISOCITRATE DEHYDROGENASE 1; PROTEIN; SPOP PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ER81; TRANSCRIPTION FACTOR ERG; TRANSCRIPTION FACTOR ETV4; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER LOCALIZATION; CANCER PROGNOSIS; CASE REPORT; CLINICAL DECISION MAKING; CLONAL EVOLUTION; FOLLOW UP; GENE EXPRESSION; GENE FREQUENCY; GENE FUSION; GENE REARRANGEMENT; GENETIC HETEROGENEITY; GENOMICS; GLEASON SCORE; HUMAN; HUMAN TISSUE; MALE; MIDDLE AGED; NONSENSE MUTATION; PHYLOGENETIC TREE; PHYLOGENY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RNA SEQUENCE; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TRANSCRIPTOMICS; WHOLE EXOME SEQUENCING; ADENOCARCINOMA; CLASSIFICATION; DISEASE EXACERBATION; GENETICS; PATHOLOGY; PROGNOSIS; PROSTATE; PROSTATE TUMOR;

ADENOCARCINOMA; AGED; DISEASE PROGRESSION; GENETIC HETEROGENEITY; GENOMICS; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS; SEQUENCE ANALYSIS;

EID: 84979519295     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2016.07.008     Document Type: Article

References (35)

1. [1] Aihara, M., Wheeler, T.M., Ohori, M., Scardino, P.T., Heterogeneity of prostate cancer in radical prostatectomy specimens. Urology 43 (1994), 60–66.
2. [2] Murphy, G.P., Busch, C., Abrahamsson, P.A., et al. Histopathology of localized prostate cancer. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993. Scand J Urol Nephrol Suppl 162 (1994), 7–42.
3. [3] Miller, G.J., Cygan, J.M., Morphology of prostate cancer: the effects of multifocality on histological grade, tumor volume and capsule penetration. J Urol 152 (1994), 1709–1713.
4. [4] Ruijter, E.T., van de Kaa, C.A., Schalken, J.A., Debruyne, F.M., Ruiter, D.J., Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications. J Pathol 180 (1996), 295–299.
5. [5] Cheng, L., Song, S.Y., Pretlow, T.G., et al. Evidence of independent origin of multiple tumors from patients with prostate cancer. J Natl Cancer Inst 90 (1998), 233–237.
6. [6] Macintosh, C.A., Stower, M., Reid, N., Maitland, N.J., Precise microdissection of human prostate cancers reveals genotypic heterogeneity. Cancer Res 58 (1998), 23–28.
7. [7] Cheng, L., Bostwick, D.G., Li, G., et al. Allelic imbalance in the clonal evolution of prostate carcinoma. Cancer 85 (1999), 2017–2022.
8. [8] Gerlinger, M., Catto, J.W., Orntoft, T.F., Real, F.X., Zwarthoff, E.C., Swanton, C., Intratumour heterogeneity in urologic cancers: from molecular evidence to clinical implications. Eur Urol 67 (2015), 729–737.
9. [9] Taylor, B.S., Schultz, N., Hieronymus, H., et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 18 (2010), 11–22.
10. [10] Barbieri, C.E., Baca, S.C., Lawrence, M.S., et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 44 (2012), 685–689.
11. [11] Berger, M.F., Lawrence, M.S., Demichelis, F., et al. The genomic complexity of primary human prostate cancer. Nature 470 (2011), 214–220.
12. [12] Baca, S.C., Prandi, D., Lawrence, M.S., et al. Punctuated evolution of prostate cancer genomes. Cell 153 (2013), 666–677.
13. [13] Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. Cell 163 (2015), 1011–1025.
14. [14] Boutros, P.C., Fraser, M., Harding, N.J., et al. Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nat Genet 47 (2015), 736–745.
15. [15] Cooper, C.S., Eeles, R., Wedge, D.C., et al. Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nat Genet 47 (2015), 367–372.
16. [16] Falzarano, S.M., Ferro, M., Bollito, E., Klein, E.A., Carrieri, G., Magi-Galluzzi, C., Novel biomarkers and genomic tests in prostate cancer: a critical analysis. Minerva Urol Nefrol 67 (2015), 211–231.
17. [17] National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Prostate cancer guidelines. www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.
18. [18] Heemers, H.V., Targeting androgen receptor action for prostate cancer treatment: does the post-receptor level provide novel opportunities?. Int J Biol Sci 10 (2014), 576–587.
19. [19] Goodwin, J.F., Schiewer, M.J., Dean, J.L., et al. A hormone-DNA repair circuit governs the response to genotoxic insult. Cancer Discov 3 (2013), 1254–1271.
20. [20] Polkinghorn, W.R., Parker, J.S., Lee, M.X., et al. Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discov 3 (2013), 1245–1253.
21. [21] Morrison, C., Cheney, R., Johnson, C.S., Smith, G., Mohler, J.L., Central quadrant procurement of radical prostatectomy specimens. Prostate 69 (2009), 770–773.
22. [22] Grasso, C.S., Wu, Y.M., Robinson, D.R., et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487 (2012), 239–243.
23. [23] Robinson, D., Van Allen, E.M., Wu, Y.M., et al. Integrative clinical genomics of advanced prostate cancer. Cell 161 (2015), 1215–1228.
24. [24] Futreal, P.A., Coin, L., Marshall, M., et al. A census of human cancer genes. Nat Rev Cancer 4 (2004), 177–183.
25. [25] Kan, Z., Jaiswal, B.S., Stinson, J., et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466 (2010), 869–873.
26. [26] Bostrom, P.J., Bjartell, A.S., Catto, J.W., et al. Genomic predictors of outcome in prostate cancer. Eur Urol 68 (2015), 1033–1044.
27. [27] Lindberg, J., Klevebring, D., Liu, W., et al. Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins. Eur Urol 63 (2013), 347–353.
28. [28] Svensson, M.A., LaFargue, C.J., MacDonald, T.Y., et al. Testing mutual exclusivity of ETS rearranged prostate cancer. Lab Invest 91 (2011), 404–412.
29. [29] Tomlins, S.A., Alshalalfa, M., Davicioni, E., et al. Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes. Eur Urol 68 (2015), 555–567.
30. [30] Knudsen, B.S., Kim, H.L., Erho, N., et al. Application of a clinical whole-transcriptome assay for staging and prognosis of prostate cancer diagnosed in needle core biopsy specimens. J Mol Diagn 18 (2016), 395–406.
31. [31] Spratt, D.E., Evans, M.J., Davis, B.J., et al. Androgen receptor upregulation mediates radioresistance after ionizing radiation. Cancer Res 75 (2015), 4688–4696.
32. [32] Kumar, A., Coleman, I., Morrissey, C., et al. Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nat Med 22 (2016), 369–378.
33. [33] Haffner, M.C., Mosbruger, T., Esopi, D.M., et al. Tracking the clonal origin of lethal prostate cancer. J Clin Invest 123 (2013), 4918–4922.
34. [34] Klein, E.A., Cooperberg, M.R., Magi-Galluzzi, C., et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol 68 (2014), 550–560.
35. [35] Faisal, F.A., Sundi, D., Tosoian, J.J., et al. Racial variations in prostate cancer molecular subtypes and androgen receptor signaling reflect anatomic tumor location. Eur Urol 70 (2016), 14–17.